Henlius 3Q 2023 Results Investor Presentation

Henlius reported 3Q 2023 revenue of RMB 1.4B (69% YoY growth) with net profit of RMB 168M. The biopharmaceutical company achieved key milestones including ESCC approval, strong sales from flagship products HANSIZHUANG and HANQUYOU, and strategic licensing deals for HLX10 with upfront payments totaling EUR 49M and USD 7M.